Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
COVID-19: In Amb. Birx, the White House gets a scientist, physician, public health expert and global health realist as response coordinator
If the criteria for the selection announced Wednesday night of Vice President Mike Pence to lead the U.S. efforts to contain the spread of COVID-19 seemed […]
As a New Pandemic Spreads, World TB Day Reminds us of Unfinished Business – Efforts to fight the latest global health threat can come at the […]
This year marks the close of a dynamic decade in global infectious disease research and responses that changed expectations of what humanity can accomplish toward making […]
COVID-19: Groups urge Congress to provide emergency funding needed for domestic, global coronavirus responses
A coalition of medical, health care, health policy and other groups are calling on the United States Congress to swiftly and meaningfully fund emergency multifaceted domestic […]